Clinical trials: Psychosis NOS
Apathy, Schizophrenia
Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.
This study is looking to determine if Lumateperone improves motivation in patients with schizophrenia or schizoaffective disorders who show high levels of apathy as judged by AES-C-Apathy (Apathy Evaluation Scale - Clinician …
- Conditions
- Apathy, Schizophrenia, Schizophrenia; Psychosis
- Trial name
- NCT06482554
- Testing
- Lumateperone 42 mg, Risperidone 2 mg
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Louisiana State University Health Sciences Center Shreveport
Acute Psychosis
Acceptance & Commitment Therapy for Psychotic Inpatients
The overarching aim of the research project is to investigate whether Acceptance \& Commitment Therapy (ACT) is an efficacious psychotherapeutic method of treatment for inpatients suffering from acute psychosis.
- Trial name
- NCT02458105
- Testing
- Acceptance & Commitment Therapy, Attention
- Where
- Sweden
- Sponsor
- Uppsala University
Obesity, Vitamin D Deficiency
Vitamin D Supplementation in Psychiatric Illnesses
Children and adolescents with psychiatric illnesses who are treated with medications called second generation antipsychotic agents (SGA) often gain excessive weight during their treatment with these medications.
- Conditions
- Obesity, Vitamin D Deficiency, Psychosis, Schizophrenia
- Trial name
- VDSS (NCT01004354)
- Testing
- Ergocalciferols
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Massachusetts, Worcester
Type 2 Diabetes Mellitus, Schizophrenia
Lifestyle Intervention for Diabetes and Weight Management in Psychosis
The rate of type-2 diabetes mellitus (T2DM) is at least 2-3 times higher in persons with psychotic illnesses than in the general population.
- Conditions
- Type 2 Diabetes Mellitus, Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- Healthy_LIFE (NCT01828931)
- Testing
- Lifestyle Intervention, Usual Care
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Centre for Addiction and Mental Health
Psychosis, Alcohol Use Disorder
Effects of Action-Based Cognitive Remediation on Substance Misuse in Early Phase Psychosis
Psychotic disorders impact 4.6 people per 1000 globally, with approximately 1.5 million Canadians affected. The age of onset for psychotic disorders often begin during the critical years of youth and early adulthood, resulting in…
- Conditions
- Psychosis, Alcohol Use Disorder, Cannabis Use Disorder
- Trial name
- NCT07056894
- Testing
- Action-Based Cognitive Remediation
- Where
- 2 sites in Canada
- Volunteers
- 50 people
- Sponsor
- Nova Scotia Health Authority
Psychosis, Mother-Child Relations
Pilot Study to Evaluate the Effectiveness of Online Familiar Metacognitive Training (MCTf)
The objective of this study is to adapt and evaluate the efficacy of Familiar Metacognitive Training (MCTf) in mothers and adolescent children in a group context with the main purpose of improving family relationships, cognitive…
- Trial name
- MCTf (NCT05358457)
- Testing
- Familiar Metacognitive Training
- Volunteers
- 48 people
- Sponsor
- Fundació Sant Joan de Déu
Artificial Intelligence, Septic Shock
Artificial Intelligence for Sepsis Prediction in ICU
The development of sepsis prediction model in line with Chinese population, and extended to clinical, assist clinicians for early identification, early intervention, has a good application prospect.
- Conditions
- Artificial Intelligence, Septic Shock, Intensive Care Unit Psychosis
- Trial name
- AICUSepsis (NCT04913181)
- Testing
- Artificial intelligence sepsis prediction model
- Volunteers
- 2,000 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Healthy Subjects
Cognitive Biases Under Ketamine
Characterise cognitive biases resulting from low dose ketamine infusion, used as a pharmacological model of psychosis. Our assumption is that low dose ketamine results in reasoning biases by impairing the way uncertainty is…
- Trial name
- KETABI (NCT02235012)
- Testing
- Ketamine
- Where
- France
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier St Anne
Psychotic Disorders
Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis
There is a substantial need for enhancing the efficacy and effectiveness of Veterans Health Administration (VHA) inpatient services for psychosis and tailoring them to support recovery.
- Trial name
- ACT-IP (NCT01981356)
- Testing
- Acceptance and Commitment Therapy, Treatment as Usual (TAU)
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Clinical High Risk, Psychosis
AMP SCZ® Observational Study: PREDICT-DPACC
The Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) is a large international collaboration to develop algorithms using a set of clinical and cognitive assessments, multi-modal biomarkers, and clinical endpoints that…
- Conditions
- Clinical High Risk, Psychosis, Remission, Conversion
- Trial name
- AMP SCZ (NCT05905003)
- Where
- 42 sites in United States, Australia and 12 more
- Volunteers
- 2,617 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
First Episode Psychosis, Schizophrenia
OnTrackNY With the Option of Social Network Meetings
Early intervention programs for psychosis help improve short-term treatment and recovery outcomes for individuals experiencing psychosis.
- Trial name
- NCT03464162
- Testing
- Social Network Meetings
- Where
- United States
- Sponsor
- Lisa Dixon
Schizophrenia Spectrum and Other Psychotic Disorders
A Randomized Controlled Trial With Rituximab for Psychotic Disorder in Adults
Immunological factors are assumed to be determinants for some psychiatric disorders, thus anti-inflammatory drugs may be helpful. However, studies on such treatments are scarce.
- Trial name
- RCT-RITS (NCT05622201)
- Testing
- Rituximab
- Where
- Sweden
- Volunteers
- 123 people
- Sponsor
- Region Örebro County
Schizophrenia, Psychotic Disorders
Enhancing the Prospective Prediction of Psychosis
This study will gather information on the natural history of the basic symptoms of psychosis to identify factors that may affect the improvement or persistence of the symptoms.
- Trial name
- NCT00291200
- Where
- 3 sites in United States, Canada
- Volunteers
- 268 people
- Sponsor
- Yale University
Schizophrenia Disorder, Schizoaffective Disorder
Improving Health Literacy in Patients With Schizophrenia Spectrum Disorder
The Impact of Health Literacy on the Attitudes toward Pharmacological Treatment in Patients with Schizophrenia Spectrum Disorder This interventional study is aimed at: assessing and improving the health literacy and assessing the…
- Conditions
- Schizophrenia Disorder, Schizoaffective Disorder, Psychosis
- Trial name
- NCT07488156
- Testing
- Educational sessions
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Louisiana State University Health Sciences Center in New Orleans
Alzheimer's Disease Psychosis
A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis
This study will evaluate the safety and efficacy of pimavanserin 40 mg compared to placebo in patients with Alzheimer's disease psychosis.
- Trial name
- NCT02035553
- Testing
- Pimavanserin tartrate
- Where
- United Kingdom
- Volunteers
- 181 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Schizoaffective Disorder, Schizophrenia
Genetic Study of Schizophrenia
This large ongoing study at NIMH investigates the neurobiology of schizophrenia by identifying susceptibility genes, evaluating their impact on brain function to better understand how to treat and prevent this illness.
- Trial name
- NCT00001486
- Where
- United States
- Volunteers
- 4,914 people
- Sponsor
- National Institute of Mental Health (NIMH)
Affective Psychosis, Bipolar, Mania
Non-interventional Study of Ziprasidone in the Treatment of Bipolar and Schizoaffective Disorders.
Assessment of ziprasidone safety and efficacy in the treatment of bipolar and schizoaffective disorders.
- Conditions
- Affective Psychosis, Bipolar, Mania, Manic-Depressive Psychosis
- Trial name
- NCT00454883
- Testing
- ziprasidone
- Volunteers
- 379 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Cognitive Functioning, Psychosis
The Effect of Combined Brain Stimulation and Yoga for Improving Cognitive Function in Psychosis
The study examines (1) the effects of active anodal (facilitatory) tDCS and yoga combined intervention on cognitive function, clinical symptoms, and quality of life domains (social function and physical wellbeing) in psychosis…
- Trial name
- NCT07747181
- Testing
- Active tDCS, Yoga
- Where
- Hong Kong
- Volunteers
- 135 people
- Sponsor
- The Hong Kong Polytechnic University
Psychosis
Can Imagination Change Upsetting Memories of Trauma?
Research suggests that imagination is a powerful tool to change images inside our heads (e.g. memories) and make them less upsetting. It is thought that this occurs through changing the meaning attached to the memory (e.g.
- Trial name
- NCT03607630
- Testing
- Imagery Rescripting
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- King's College London
Affective Disorder, Psychosis
Value of Gym-based Exercise Training for Young Adults Receiving Antipsychotic Medication: The Vega Trial
This is a multicentre, pragmatic, randomised controlled trial to estimate the effect of a 4-month gym-based exercise training program on 1) patient-rated personal recovery (primary outcome), 2) Health-related quality of life…
- Trial name
- Vega (NCT05461885)
- Testing
- Supervised exercise
- Where
- 4 sites in Denmark
- Volunteers
- 226 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet